Clinical Trials Sponsored by Mats Hammar

Total 657 results

Mats Hammar
Linkoeping University

Terminated

Climacteric Therapy With Applied Relaxation Using InterNet (CARIN)

Hot Flashes | Menopause

Sweden
Mars Wrigley

Completed

Salivary Flow Promoted by Sugar-Free Chewing Gum

Saliva Altered

United States
Mats Bågesund
Linkoeping University

Completed

Equal Oral Health in Children: The Hageby-model (EOH)

Dental Caries in Children | Pregnancy Related | Infant Conditions | Risk Reduction | Educational Problems | Economic Problems | Child, Preschool

Sweden
Centre Hospitalier le Mans
Le Mans Universite

Recruiting

Physiopathology of Neuromuscular Function Related to Fatigue in Chronic Renal Disease (PIONEER)

Fatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3B

France
Mats Bågesund
Linkoeping University

Completed

Sealing of Occlusal Dentin Caries in Primary Molars. (SealCar)

Dental Caries in Children | Caries; Dentin | Fissure Sealants | Fissure, Dental | Glass Ionomer Cement
Mats Lekander
Stockholm University

Completed

The Stockholm Sleepy Brain Study: Effects of Sleep Deprivation on Cognitive and Emotional Processing in Young and Old

Sleep Deprivation

Sweden
Y-mAbs Therapeutics

Not yet recruiting

Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma

United States
Y-mAbs Therapeutics

Recruiting

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Sarcoma | SCLC | Malignant Melanoma

United States
Y-mAbs Therapeutics

Recruiting

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Neuroblastoma

Spain, Denmark, United States, Italy, United Kingdom, Germany, Hong Kong, Canada, France
Y-mAbs Therapeutics

Terminated

Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma

Neuroblastoma Recurrent

Korea, Republic of, Hong Kong
Y-mAbs Therapeutics

Terminated

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

Medulloblastoma, Childhood

United States, Spain, United Kingdom, Denmark, Netherlands
Mati Therapeutics Inc.

Completed

An Open-Label, Multi-Center, Clinical Study Evaluating the Effect of the NDE L68 StableFit® Punctal Plug on the Tear Lake

Dry Eye Syndromes

United States
Mati Therapeutics Inc.

Completed

A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma

Ocular Hypertension | Open-Angle Glaucoma

United States
Mast Therapeutics, Inc.

Completed

Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer

Healthy Volunteers | Renal Impaired | Pharmacokinetics of Vepoloxamer

United States
Mast Therapeutics, Inc.

Terminated

Evaluation of Vepoloxamer in Chronic Heart Failure

Chronic Heart Failure

United States, Australia
The Maas Clinic

Unknown

A Clinical Study Comparing Restylane® Silk and Belotero Balance® for the Treatment of Superficial, Vertical Perioral Lines

Perioral Rhytids

United States
Mast Therapeutics, Inc.

Terminated

Evaluation of MST-188 in Acute Lower Limb Ischemia

Acute Limb Ischemia

United States
Mast Therapeutics, Inc.

Completed

ANX-188 Thorough QT/QTc Study in Healthy Volunteers

Healthy

United States
Mati Therapeutics Inc.

Completed

A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Ocular Hypertension | Open Angle Glaucoma

Canada
Mati Therapeutics Inc.

Completed

A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

Ocular Hypertension | Glaucoma

United States
Mati Therapeutics Inc.

Completed

A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Mast Therapeutics, Inc.

Completed

A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer

Advanced Cancer

United States, Argentina, Estonia
Mast Therapeutics, Inc.

Completed

A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.

Healthy Adults

United States
MAST Biosurgery, AG

Completed

Evaluation of Bioresorbable Sheet to Prevent Intra-Abdominal Adhesions in Colorectal Surgeries

Adhesions

Norway
Mast Therapeutics, Inc.

Unknown

5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients

Breast Cancer

Argentina, Mexico, Peru, Russian Federation, Spain
Mast Therapeutics, Inc.

Unknown

Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

Metastatic Colorectal Cancer | Rectal Cancer | Colon Cancer

United States, Former Serbia and Montenegro
Centre Hospitalier le Mans
Le Mans Universite

Withdrawn

Pathophysiological Characterization of the Neuromuscular Function of a Population With Multiple Comorbidities Suffering From Chronic Renal Failure in Pre-dialysis. (PIONNIER)

Fatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
Y-mAbs Therapeutics

Terminated

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Neuroblastoma | Leptomeningeal Metastases | CNS Metastases

United States, Denmark, Japan, Spain
Y-mAbs Therapeutics

Terminated

Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

Peritoneal Cancer

United States
Mati Therapeutics Inc.

Completed

Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure

Elevated Intraocular Pressure (IOP)

United States
Y-mAbs Therapeutics

Terminated

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Osteosarcoma | Neuroblastoma | Other Solid Tumor Cancers

United States
Y-mAbs Therapeutics

Terminated

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

SCLC

United States
Y-mAbs Therapeutics

Withdrawn

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Neuroblastoma

Korea, Republic of, Singapore, Hong Kong, Russian Federation
Mast Therapeutics, Inc.

Completed

Evaluation of Repeat Administration of Purified Poloxamer 188 (EPIC-E)

Sickle Cell Disease

United States
Mati Therapeutics Inc.

Completed

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Glaucoma | Ocular Hypertension (OH)

United States
Mati Therapeutics Inc.

Completed

Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension (CORE)

Ocular Hypertension | Glaucoma

United States
Le Mans Universite

Active, not recruiting

BIOpsychosocial Approach of the CAncer-RElated FAtigue (BIOCARE FActory)

Breast Cancer

France
Y-mAbs Therapeutics

Withdrawn

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Solid Tumor, Adult | Leptomeningeal Metastasis

United States, United Kingdom
Mati Therapeutics Inc.

Completed

Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract

Pain | Inflammation

United States
Mast Therapeutics, Inc.

Completed

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) (EPIC)

Sickle Cell Disease | Vaso-occlusive Crisis

United States, Belgium, Brazil, Dominican Republic, Jamaica, Jordan, Lebanon, Oman, Panama, Spain, Turkey
Mati Therapeutics Inc.

Completed

A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Glaucoma | Ocular Hypertension (OH)

United States
Mati Therapeutics Inc.

Completed

Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Mati Therapeutics Inc.

Terminated

A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.

Seasonal Allergic Conjunctivitis to Ragweed

Canada
Mati Therapeutics Inc.

Withdrawn

A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Ocular Hypertension | Glaucoma
Mast Therapeutics, Inc.

Completed

Clinical Trial in Patients With Metastatic Colorectal Cancer

Rectal Cancer | Colon Cancer

United Kingdom, Serbia, India, Poland, Romania
Centre Hospitalier le Mans

Not yet recruiting

Impact of the Choice of Gastric Tube Placement Sites on the Incidence of Ventilator Associated Pneumonia (SONG)

Intubated Patient Requiring a Gastric Tube

France
Centre Hospitalier le Mans

Not yet recruiting

Mean Arterial Pressure After Out-of-hospital Cardiac Arrest (METAPHORE)

Cardiac Arrest

France
Centre Hospitalier le Mans

Recruiting

Development of a Personalised Therapeutic Approach for Cancer Patients With Resting Hypermetabolism (METABO-1)

Cancer

France
Mads Ersbøll

Recruiting

Dapagliflozin in Pulmonary Arterial Hypertension (DAPAH)

Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary Hypertension

Denmark
Centre Hospitalier le Mans

Recruiting

Validation of a Predictive Rule for the Diagnosis of Viral Meningitis in Adult Emergency Departments (Adult-BMS)

Meningitis

France

3

Subscribe